Lipocine Z Score
LPCN   USA Stock  USD 0.91 0.03 3.19% 
Lipocine Z Score  Lipocine Z Score 
Lipocine Z Score Analysis
Lipocine's ZScore is a simple linear, multifactor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..2019  2020  2021  2022 (projected)  
Enterprise Value  6.05 M  77.75 M  69.98 M  65.27 M 
Average Equity  9.05 M  12.37 M  11.13 M  14.45 M 
Z Score  =  Sum Of   5 Factors 
Current Lipocine Z Score  9.8 
Most of Lipocine's fundamental indicators, such as Z Score, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lipocine is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
 
 
 
 

Lipocine Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Lipocine is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Z Score. Since Lipocine's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lipocine's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lipocine's interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate ZScore one would need to know current working capital of the company, its total assets, and liabilities, amount of latest retained earnings as well as earnings before interest and tax. ZScore can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with ZScores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a socalled 'grey area' with scores of less than 1, indicating the high probability of distress. Z Score is used widely by financial auditors, accountants, money managers, loan processers, wealth advisers, as well as day traders. In the last 25 years, many financial models that utilize z score has been proved to be successful as a predictor of corporate bankruptcy.
Compare to competition 
Based on the company's disclosures, Lipocine has a Z Score of 9.8. This is 45.19% higher than that of the Healthcare sector and 193.41% higher than that of the Biotechnology industry. The z score for all United States stocks is 12.39% lower than that of the firm.
Lipocine Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lipocine's direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lipocine could also be used in its relative valuation, which is a method of valuing Lipocine by comparing valuation metrics of similar companies.Lipocine is currently under evaluation in z score category among related companies.
Lipocine Current Valuation Drivers
We derive many important indicators used in calculating different scores of Lipocine from analyzing Lipocine's financial statements. These drivers represent accounts that assess Lipocine's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Lipocine's important valuation drivers and their relationship over time.
2017  2018  2019  2020  2021  2022 (projected)  
Net Income Per Employee  (1.35 M)  (1.5 M)  (1.17 M)  (1.08 M)  (1.25 M)  (1.34 M)  
Average Assets  26.71 M  25.13 M  19.92 M  23.65 M  27.19 M  29.01 M  
Earnings Before Interest Taxes and Depreciation Amortization EBITDA  (20.95 M)  (11.64 M)  (12.22 M)  (20.57 M)  (18.52 M)  (19.98 M)  
Earnings Before Interest Taxes and Depreciation Amortization USD  (20.95 M)  (11.64 M)  (12.22 M)  (20.57 M)  (18.52 M)  (19.98 M)  
Earnings before Tax  (20.98 M)  (11.66 M)  (13.01 M)  (20.96 M)  (18.87 M)  (20.36 M)  
Average Equity  23.19 M  12.94 M  9.05 M  12.37 M  11.13 M  14.45 M  
Enterprise Value  63.65 M  28.3 M  6.05 M  77.75 M  69.98 M  65.27 M  
Free Cash Flow  (16.7 M)  (12.08 M)  (11.67 M)  (15.3 M)  (13.77 M)  (14.86 M)  
Invested Capital  15.77 M  13.54 M  7.11 M  142.07 K  163.38 K  167.68 K  
Invested Capital Average  14.18 M  21.61 M  11.44 M  4.36 M  5.01 M  5.14 M  
Market Capitalization  72.92 M  27.9 M  9.78 M  89.33 M  80.4 M  77.14 M  
Tangible Asset Value  25.33 M  20.85 M  19.66 M  25.35 M  29.16 M  29.45 M  
Working Capital  18.87 M  16.32 M  14.67 M  18.75 M  21.56 M  23.64 M 
Lipocine Fundamentals
Return On Equity  (75.11) %  
Return On Asset  (27.71) %  
Current Valuation  50.25 M  
Shares Outstanding  88.29 M  
Shares Owned by Insiders  2.53 %  
Shares Owned by Institutions  10.48 %  
Number of Shares Shorted  3.6 M  
Price to Earning  (11.04) X  
Price to Book  2.21 X  
Revenue  54.99 K  
Gross Profit  (5.05 M)  
EBITDA  (14.44 M)  
Net Income  (17.77 M)  
Cash and Equivalents  38.66 M  
Cash per Share  0.44 X  
Total Debt  3.27 M  
Debt to Equity  0.1 %  
Current Ratio  6.28 X  
Book Value Per Share  0.48 X  
Cash Flow from Operations  (17.09 M)  
Short Ratio  7.24 X  
Earnings Per Share  (0.28) X  
Number of Employees  13  
Beta  0.33  
Market Capitalization  93.59 M  
Total Asset  29.55 M  
Retained Earnings  (155.04 M)  
Working Capital  27.84 M  
Current Asset  29.41 M  
Current Liabilities  1.57 M  
Z Score  9.8 
About Lipocine Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lipocine's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lipocine using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lipocine based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Lipocine Inc., a clinicalstage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of metabolic and endocrine disorders. The companys pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase II Clinical trial for the treatment of noncirrhotic nonalcoholic steatohepatitis TLANDO XR, an oral prodrug of testosterone for once daily dosing, which has completed Phase II clinical trial in hypogonadal men LPCN 1148, an oral prodrug of bioidentical testosterone that has completed phase I clinical trial for the treatment of NASH cirrhosis and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. Lipocine operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Lipocine without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.riskadjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Aroon Oscillator Now
Aroon OscillatorAnalyze current equity momentum using Aroon Oscillator and other momentum ratios 
All Next  Launch Module 
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Lipocine using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Additionally, see Lipocine Piotroski F Score and Lipocine Valuation analysis. Note that the Lipocine information on this page should be used as a complementary analysis to other Lipocine's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Complementary Tools for Lipocine Stock analysis
When running Lipocine price analysis, check to measure Lipocine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lipocine is operating at the current time. Most of Lipocine's value examination focuses on studying past and present price action to predict the probability of Lipocine's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Lipocine's price. Additionally, you may evaluate how the addition of Lipocine to your portfolios can decrease your overall portfolio volatility.
Bond AnalysisEvaluate and analyze corporate bonds as a potential investment for your portfolios.  Go  
Positions RatingsDetermine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and riskadjusted market performance  Go  
Equity ValuationCheck real value of public entities based on technical and fundamental data  Go  
Alpha FinderUse alpha and beta coefficients to find investment opportunities after accounting for the risk  Go  
Price Ceiling MovementCalculate and plot Price Ceiling Movement for different equity instruments  Go  
Bollinger BandsUse Bollinger Bands indicator to analyze target price for a given investing horizon  Go 
The market value of Lipocine is measured differently than its book value, which is the value of Lipocine that is recorded on the company's balance sheet. Investors also form their own opinion of Lipocine's value that differs from its market value or its book value, called intrinsic value, which is Lipocine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipocine's market value can be influenced by many factors that don't directly affect Lipocine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipocine's value and its price as these two are different measures arrived at by different means. Investors typically determine Lipocine value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipocine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.